Suicidal ideation among children taking atomoxetine (Strattera)

CMAJ. Canadian Medical Association Journal

Volumn 173, Issue 12, 2005, Pages 1447-

  Wooltorton, Eric ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

ATOMOXETINE; METHYLPHENIDATE;

APPETITE DISORDER; ARTICLE; ATTENTION DEFICIT DISORDER; CONSTIPATION; DIZZINESS; DRUG EFFICACY; DRUG HALF LIFE; DRUG MARKETING; DYSMENORRHEA; EJACULATION DISORDER; ERECTILE DYSFUNCTION; FATIGUE; FOOD AND DRUG ADMINISTRATION; GASTROINTESTINAL DISEASE; GENETIC POLYMORPHISM; GROWTH RETARDATION; HUMAN; LIVER TOXICITY; MOOD DISORDER; MOTOR DYSFUNCTION; NAUSEA; SEDATION; SIDE EFFECT; SLEEP DISORDER; SUICIDE ATTEMPT; URINARY HESITANCY; VOMITING; WEIGHT REDUCTION; XEROSTOMIA;

EID: 28844469813     PISSN: 08203946     EISSN: 14882329     Source Type: Journal    
DOI: 10.1503/cmaj.051474     Document Type: Article

References (3)

1. Warning for atomoxetine regarding the potential for behavioural and emotional changes, including risk of self harm. [Dear Healthcare Professional Letter]. Available: www.hc-sc.gc.ca/dhp-mps /medeff/advisories-avis/prof/ strattera_hpc-cps_e .html (accessed 9 Nov 2005).
2. Atomoxetine (Strattera) for ADHD. The Medical Letter 2003;45(1149):11-2.
3. Atomoxetine (Strattera) Revisited. The Medical Letter 2004;46(1189):65.